An international survey on the use of intrapleural tissue plasminogen activator/DNase therapy for pleural infection Source: ERJ Open Res, 8 (1) 00590-2021; 10.1183/23120541.00590-2021 Year: 2022
Intrapleural urokinase in the management of empyema in children Source: Eur Respir J 2004; 24: Suppl. 48, 620s Year: 2004
Intrapleural fibrinolytic treatment with streptokinase for empyema during pregnancy: 2 cases Source: Annual Congress 2010 - Infections and pleural problems Year: 2010
Comparison of intrapleural use of urokinase and tissue plasminogen activator/DNAse in pleural infection Source: ERJ Open Res, 5 (3) 00084-2019; 10.1183/23120541.00084-2019 Year: 2019
Half - dose of recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism: long term outcomes Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017
The biological effect of intrapleural tissue plasminogen (tPA) activator and DNase delivery in pleural infection patients. Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies Year: 2018
A clinical comparison of intrapleural heparin versus urokinase in the management of tuberculous pleurisy Source: Eur Respir J 2005; 26: Suppl. 49, 647s Year: 2005
Outcomes of intrapleural tissue plasminogen activator (tPA) and deoxyribnuclease (DNase) for IPC-related pleural infection Source: International Congress 2019 – Pleural infection and complicated pneumonia Year: 2019
Intrapleural fibrinolytic treatment of empyemas Source: Eur Respir J 2005; 26: Suppl. 49, 491s Year: 2005
Efficacy of thrombolytic agents in the treatment of pulmonary embolism Source: Eur Respir J 2005; 26: 864-874 Year: 2005
Intrapleural instillation of fibrinolytics in the treatment complicated pneumonia in children. Case study Source: Eur Respir J 2002; 20: Suppl. 38, 591s Year: 2002
Ten years experience of use of intrapleural streptokinase (IPSK) for empyema Source: Eur Respir J 2001; 18: Suppl. 33, 319s Year: 2001
Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNAse) for pleural infection in an Asian population: Similar outcomes between 5mg and 10mg regimen Source: International Congress 2018 – Clinical challenges in respiratory infection Year: 2018
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia Source: ERJ Open Res, 5 (1) 00212-2018; 10.1183/23120541.00212-2018 Year: 2019
Intrapleural streptokinase for empyema and complicated parapneumonic effusions: a randomised controlled trial Source: Annual Congress 2004 - New diagnostic and therapeutic applications in bronchoscopy and thoracoscopy Year: 2004
Intrapleural streptokinase therapy in tubercular pleural effusions – Randomized controlled study Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment Year: 2013
Effectiveness and safety of tissue plasminogen activators (t-PA) in complicated pleural effusion (CPE), what the correlation with time it stays in the pleural space? Source: Annual Congress 2013 –A modern approach to lung diseases: from bronchi to pleura Year: 2013
Observational study of the use of recombinant tissue-type plasminogen activator in COVID-19 shows a decrease in physiological dead space Source: ERJ Open Res, 6 (4) 00455-2020; 10.1183/23120541.00455-2020 Year: 2020
Safety and efficacy of reduced dose intrapleural alteplase and DNAase for pleural infection Source: International Congress 2018 – Difficult-to-treat respiratory infections Year: 2018
Intrapleural heparin or heparin combined with human recombinant DNAase is not effective in the treatment of empyema in a rabbit model Source: Eur Respir J 2006; 28: Suppl. 50, 348s Year: 2006